Merck KGaA to end API work at Irish plant after ‘strategic portfolio review’
Merck KGaA is ending its API production work in Arklow, Ireland, and is proposing to shut down its factory at the end of 2028, a company spokesperson told Endpoints News. The company made the ...
View ArticlePost-Hoc: Why we tracked pharma’s private jet flights to DC
Earlier this year, I asked our reporter Max Bayer how we might keep track of pharma’s influence in Washington, DC. The usual way of tracking the relationship between corporations and the US government...
View ArticleHealth tech investors are getting picky
We’re back home recovering from HLTH, where four days of nonstop meetings with executives and investors sharpened our view of where money is going in health tech. And when it comes to the state of ...
View ArticleFDA provides new checklists to prevent drug submission delays
One of the more embarrassing potential moments for a biopharma company comes when it receives a refuse-to-file (RTF) letter from the FDA. The letter doesn't signal anything to the public on whether the...
View ArticleInhibrx will head to FDA for bone cancer drug next year after strong data
Inhibrx released striking new data for one of its cancer programs Thursday afternoon across a range of hard-to-treat tumors, and plans to take the results to regulators by next year. The biotech said...
View ArticleFDA brings GSK's Blenrep back to the market in multiple myeloma
The FDA has approved GSK's Blenrep as a third-line multiple myeloma drug, overcoming a negative advisory committee vote and clearing the way for a relaunch in the US. The approval comes after a...
View ArticleSanofi’s Dupixent sales continue to deliver as ‘negative buzz’ impacts...
Sanofi posted robust third-quarter sales on Friday, backed by the continued growth of its blockbuster drug Dupixent. But the French pharma said its Q3 vaccine sales dipped about 8% from the ...
View ArticleNovo Nordisk lines up corporate affairs exec, overshadowed by board drama
→ In addition to the hullabaloo surrounding its board of directors, Novo Nordisk has filled a crucial role as it wrestles with President Donald Trump’s drug pricing demands. Greg Miley
View ArticleZai Lab shares Phase 1 data for lung cancer drug that could spar with Amgen’s...
Zai Lab on Friday reported updated early-stage data for its closely-watched ADC candidate that could compete with Amgen’s Imdelltra. Both drugs target the DLL3 protein and are designed to treat...
View ArticleMerus makes push into colorectal cancer with early positive data
Merus on Friday released new data for its drug petosemtamab in multiple lines of colorectal cancer, potentially giving it additional utility beyond its primary focus of head and neck tumors. In...
View ArticleRemix reveals first signs of tumor shrinkage with small molecule mRNA degrader
Remix Therapeutics, which is developing a new way to shut down the expression of cancer-causing genes, has seen the first signs of success in a rare salivary gland cancer. The company is developing...
View ArticleEli Lilly to seek Olumiant approval in adolescents with alopecia
Eli Lilly said Friday it plans to ask the FDA for a label expansion of its immunology drug Olumiant in adolescents with alopecia after successful long-term data. At one year of follow-up, Lilly said 54...
View ArticleBiogen pays $70M upfront to Vanqua Bio for immunology drug
Biogen is giving C5aR1 another go. It's paying $70 million upfront to Vanqua Bio for exclusive global rights to the Chicago startup's preclinical C5aR1 antagonist dubbed VQ-201 and up to ...
View ArticleFDA rejects Sydnexis’ myopia drug for kids; Chugai to buy Renalys for $98M...
Plus, news about Kura Oncology, X4 Pharmaceuticals, Coya Therapeutics, Harbour BioMed and Silver Creek: 👁️ FDA rejects Sydnexis’ experimental myopia drug: The company said the regulator does not...
View ArticleLilly expands gene therapy work with Adverum acquisition
Eli Lilly is bolstering its gene therapy portfolio at a time when other large drugmakers are reassessing their work in the complex and commercially challenging field. The Indianapolis-based drug giant
View ArticlePhilly is on Lilly's radar for next Gateway Labs site
Eli Lilly is considering the City of Brotherly Love as a possible next home for its next Gateway Labs site. The pharma giant recently posted a job opening for the "site ...
View ArticleHalda reveals first clinical data of RIPTAC drug in prostate cancer
Halda Therapeutics, a startup developing a new class of small molecule drugs to target and destroy cancer cells, has unveiled a promising first cut of data from an ongoing study in prostate cancer. The...
View ArticleFDA uncovers unauthorized Indian API warehouse with lizards, cats
The FDA sent an unusual inspection report late last month to the Indian generic drugmaker Hetero Labs after uncovering an unauthorized warehouse holding drugs and active pharmaceutical ingredients...
View ArticleFDA approves Bayer's hot flash treatment
The FDA has approved Bayer’s treatment for hot flashes caused by menopause, bolstering the company’s women’s health portfolio. Bayer said Friday that Lynkuet is the first dual neurokinin-targeted...
View ArticleTracking pharma’s flights to DC; Novo’s boardroom drama; #ESMO25 recap from...
Hello and welcome back to another edition of Endpoints Weekly! We had a huge week of stories, including all the highlights from our reporters in Berlin for the annual ESMO conference. That includes our...
View Article